Options for patients with irritable bowel syndrome: Contrasting traditional and novel serotonergic therapies

Neurogastroenterology and Motility

Volumn 16, Issue 6, 2004, Pages 701-711

  Johanson, J F ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Rockford Gastroenterology Associates   (United States)

Author keywords

Alosetron; Constipation; Irritable bowel syndrome; Serotonin; Tegaserod; Treatment

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BULKING AGENT; CIMETROPIUM; DESIPRAMINE; DICYCLOVERINE; DILTIAZEM; DOXEPIN; HYOSCYAMINE; ISPAGULA; LAXATIVE; LOPERAMIDE; MEBEVERINE; NEUROTRANSMITTER; POLOXAMER; POLYCARBOPHIL CALCIUM; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; TRIMIPRAMINE; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; BLOATING; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CORN; DIARRHEA; DISEASE EXACERBATION; DYSTHYMIA; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPNOSIS; INTESTINE FUNCTION; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE SECRETION; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; MICTURITION DISORDER; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RELAXATION TRAINING; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISCERA; WEIGHT GAIN; WHEAT BRAN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDIARRHEALS; CARBOLINES; CATHARTICS; HUMANS; INDOLES; INTESTINES; IRRITABLE BOWEL SYNDROME; PARASYMPATHOLYTICS; SEROTONIN; SEROTONIN AGENTS;

EID: 11144290758     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2004.00550.x     Document Type: Review

References (70)

1. Brandt LJ, Locke GR, Olden K et al. An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97(Suppl.): S1-28.
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
3. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-4.
4. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): II43-7.
5. American Heart Association. 2002 Heart and Stroke Statistical Update Dallas, TX: American Heart Association, 2002: 1-35.
6. Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Aff (Milwood) 2001; 20: 233-41.
7. American Gastroenterological Association. The Burden of Gastrointestinal Diseases Bethesda, MD: American Gastroenterological Association, 2001: 1-86 (available at: http://www.gastro.org/pdf/burden-report.pdf).
8. Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care 2001; 7(Suppl. 8): S268-75.
9. International Foundation for Functional Gastrointestinal Disorders. IBS in the Real World Survey Milwaukee, WI: International Foundation for Functional Gastrointestinal Disorders, 2002: 1-19.
10. Gralnek IM. Health care utilization and economic issues in irritable bowel syndrome. Eur J Surg 1998; 164(Suppl.): 73-6.
11. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002; 24: 675-89.
12. El Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-85.
13. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
14. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86.
15. Schoenfeld P, Chey WD, Drossman D, Kim HM, Thompson WG. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomized control trials. Gastroenterology 2002; 122(Suppl.): A465.
16. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510.
17. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61.
18. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
19. Lembo T, Rink R. Current pharmacologic treatments of irritable bowel syndrome. Participate 2002; 11: 1-4.
20. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 153-6.
21. Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 48-53.
22. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
23. Wald A. Psychotrophic agents in irritable bowel syndrome. J Clin Gastroenterol 2002; 35(Suppl): S53-7.
24. Rosemore JG, Lacy BE. Irritable bowel syndrome: basis of clinical management strategies. J Clin Gastroenterol 2002; 35(Suppl): S37-44.
25. Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome: a controlled, crossover study. Gastroenterology 1990; 98: 66-72.
26. Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut 1987; 28: 221-5.
27. Bijkerk CJ, Muris JVM, Knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-51.
28. Walker EA, Katon WJ, Jemelka RP, Roy-Bryne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study. Am J Med 1992; 92: 26S-30.
29. Lea R, Houghton LA, Calvert EL et al. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 635-42.
30. Zacker C, Albers LA, Chawla A, Wang S.Drug utilization patterns in patients with irritable bowel syndrome. Presented at: Drug Information Association Annual Meeting, June 22, 2000, San Diego, CA.
31. Hunt RH. Evolving concepts in the pathophysiology of functional gastrointestinal disorder. J Clin Gastroenterol 2002; 35(Suppl): S2-6.
32. Wood JD. Neuropathophysiology of irritable bowel syndrome. J Clin Gastroenterol 2002; 35(Suppl.): S11-22.
33. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care 2001; 7(Suppl. 8): S252-60.
34. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(Suppl. 2): 15-30.
35. Ringel Y, Drossman DA. Irritable bowel syndrome: classification and conceptualization. J Clin Gastroenterol 2002; 35(Suppl.): S7-10.
36. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-80.
37. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001; 63: 188-94.
38. Spiller RC. Role of nerves in enteric infection. Gut 2002; 51: 759-62.
39. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003; 285: G207-16.
40. Novartis Pharmaceuticals Corporation. Zelnorm (tegaserod maleate) Prescribing Information East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2002.
41. GlaxoSmithKline. Lotronex (alosetron hydrochloride) Prescribing Information Research Triangle Park, NC: GlaxoSmithKline, 2002.
42. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112: 64-72.
43. Mertz H, Morgan V, Tanner G et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118: 842-8.
44. Chang L, Berman S, Mayer EA et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003; 98: 1354-61.
45. Naliboff BD, Berman S, Chang L et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 2003; 124: 1738-47.
46. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 474-80.
47. 4 receptors. Neurogastroenterol Motil 1998; 10: 459.
48. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14: 221-7.
49. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-85.
50. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 775-82.
51. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
52. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000; 355: 1035-40.
53. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
54. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1419-27.
55. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
56. 4 receptor agonist, accelerates gastrointestinal (GI) transit. Gastroenterology 2000; 118: A845.
57. Prather CM, Camilleri M, Zinsmeister AR, Thomforde G, McKinzie S. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
58. Petrig C, Templeton J, Matzinger D, Ruegg P, Beglinger C, Degen L. Effect of tegaserod on gastrointestinal transit in male and female subjects. Gut 2002; 51(Suppl. III): A138.
59. 4 receptor agonist. Gastroenterology 1999; 116(Suppl. 2): A643.
60. Petrig C, Templeton J, Matzinger D, Ruegg P, Beglinger C, Degen L. Effect of tegaserod on faecal water and electrolyte secretion in male and female subjects. Gut 2002; 51(Suppl. III): A249.
61. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
62. 4receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
63. Lefkowitz MP, Ruegg P, Shi Y, Dunger-Baldauf C. Relief of overall gastrointestinal symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with tegaserod. Gastroenterology 1999; 116: A1027.
64. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
65. Nyhlin H, Bang C, Elsborg L et al. Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population. Gastroenterology 2003; 124(Suppl. 1): A389.
66. Tougas G, Snape WJ, Otten MH et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701-8.
67. Fidelholtz J, Smith W, Rawls J et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002; 97: 1176-81.
68. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97: 2321-7.
69. (4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41: 1021-42.
70. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Onkologie 2000; 23: 597-602.